Cover Image
Market Research Report

GLOBAL DIABETES DRUGS MARKET FORECAST 2018-2026

Published by Inkwood Research Product code 618296
Published Content info 120 Pages
Delivery time: 1-2 business days
Price
Back to Top
GLOBAL DIABETES DRUGS MARKET FORECAST 2018-2026
Published: April 9, 2018 Content info: 120 Pages
Description

KEY FINDINGS

The global diabetes drug market is mainly being driven by rising obesity amongst the population, growing elderly population and advancements in the insulin technology. Over the forecast years of 2018-2026, the global diabetes drugs market is expected to evolve further at a 6.49% CAGR.

MARKET INSIGHTS

The global diabetes drugs market is segmented on the basis of product class and diabetes type. The product class is further sub-segmented into insulin and non-insulin. The insulin product class includes long-acting, intermediate-acting and fast acting insulin, whereas the non-insulin class includes DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 receptors agonists. By diabetes type, the global diabetes drugs market is segmented into type 1 and type 2 diabetes.

REGIONAL INSIGHTS

Regionally, the global diabetes drugs market is segmented into Asia Pacific, Europe, North America and rest of the world. Presently the North American region dominates the global diabetes drugs market. A high obesity rate in the region is increasing the risk of diabetes in the region. By the end of the forecast period, the Asia-Pacific market is expected to showcase the highest CAGR. Emerging countries in this region hold much promise due to big market players due to a huge patient pool of underserved patients.

COMPETITIVE INSIGHTS

Some of the key companies engaged in this market are AstraZeneca Plc, Eli Lilly And Company, B.Braun Melsungen Ag, Novo Nordisk A/S, Sanofi, Diavacs Inc, Xoma Corp, Albireo Pharma Inc, Macrogenics Inc, Astellas Pharma, GlaxoSmithKline, Merck, Pfizer, Xeris Pharmaceuticals

Table of Contents
Product Code: 16335

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. NORTH AMERICA CAPTURED THE LARGEST CHUNK OF THE OVERALL MARKET
    • 3.2.2. RISING PREVALENCE OF TYPE 2 DIABETES
    • 3.2.3. INSULIN MARKET IS ANTICIPATED TO GENERATE THE HIGHEST REVENUE

4. MARKET DYNAMICS

  • 4.1. ETYMOLOGY OF DIABETES DRUGS MARKET
  • 4.2. MARKET DEFINITION AND SCOPE
  • 4.3. LEGAL, POLICY AND REGULATORY ISSUES
  • 4.4. MARKET DRIVERS
    • 4.4.1. INCREASE IN PREVALENCE OF DIABETES
    • 4.4.2. ADVANCES IN INSULIN TECHNOLOGY
    • 4.4.3. GROWING ELDERLY POPULATION
  • 4.5. MARKET RESTRAINTS
    • 4.5.1. STRINGENT REGULATORY CONDITIONS AND GUIDELINES FOR BIOSIMILAR DRUGS
    • 4.5.2. LACK OF AWARENESS AMONG PEOPLE
    • 4.5.3. COST SENSITIVITY ISSUES
  • 4.6. MARKET OPPORTUNITIES
    • 4.6.1. DEVELOPMENT OF NEW FORMULATIONS
    • 4.6.2. INCREASING RESEARCH AND DEVELOPMENT
  • 4.7. MARKET CHALLENGES
    • 4.7.1. FIERCE MARKET COMPETITION
    • 4.7.2. RISING CONCERNS IN SCIENTIFIC COMMUNITY
    • 4.7.3. GAPS IN NATIONAL-LEVEL DIABETES MANAGEMENT PLANS
    • 4.7.4. POOR STORAGE CONDITIONS AND DISTRIBUTION POLICIES FOR INSULIN

5. MARKET BY DIABETES TYPE

  • 5.1. TYPE 1
  • 5.2. TYPE 2

6. MARKET BY PRODUCT CLASS

  • 6.1. INSULIN
    • 6.1.1. FAST ACTING INSULIN
    • 6.1.2. INTERMEDIATE ACTING INSULIN
    • 6.1.3. LONG-ACTING INSULIN
  • 6.2. NON INSULIN
    • 6.2.1. DPP-4 INHIBITOR
    • 6.2.2. GLP-1 RECEPTORS AGONISTS
    • 6.2.3. SGLT-2 INHIBITORS
    • 6.2.4. OTHERS

7. KEY ANALYTICS

  • 7.1. PORTER'S FIVE FORCE MODEL
    • 7.1.1. THREAT OF NEW ENTRANTS
    • 7.1.2. THREAT OF SUBSTITUTE
    • 7.1.3. BARGAINING POWER OF SUPPLIERS
    • 7.1.4. BARGAINING POWER OF BUYERS
    • 7.1.5. THREAT OF COMPETITIVE RIVALRY
  • 7.2. OPPORTUNITY MATRIX
  • 7.3. VENDOR LANDSCAPE
  • 7.4. PIPELINE ANALYSIS
  • 7.5. KEY BUYING CRITERIA
    • 7.5.1. SAFETY AND EFFICACY
    • 7.5.2. AVAILABILITY
    • 7.5.3. LONG TERM RELIEF
    • 7.5.4. AFFORDABILITY AND COST-EFFECTIVENESS
    • 7.5.5. REIMBURSEMENT OF PRESCRIPTION DRUGS

8. GEOGRAPHICAL ANALYSIS

  • 8.1. NORTH AMERICA
    • 8.1.1. UNITED STATES
    • 8.1.2. CANADA
  • 8.2. EUROPE
    • 8.2.1. UNITED KINGDOM
    • 8.2.2. FRANCE
    • 8.2.3. GERMANY
    • 8.2.4. RUSSIA
    • 8.2.5. ITALY
    • 8.2.6. DENMARK
    • 8.2.7. NORWAY
    • 8.2.8. AUSTRIA
    • 8.2.9. SWITZERLAND
    • 8.2.10. SWEDEN
    • 8.2.11. NETHERLANDS
    • 8.2.12. REST OF EUROPE
  • 8.3. ASIA-PACIFIC
    • 8.3.1. CHINA
    • 8.3.2. INDIA
    • 8.3.3. AUSTRALIA
    • 8.3.4. JAPAN
    • 8.3.5. SOUTH KOREA
    • 8.3.6. INDONESIA
    • 8.3.7. MALAYSIA
    • 8.3.8. PHILIPPINES
    • 8.3.9. THAILAND
    • 8.3.10. VIET NAM
    • 8.3.11. REST OF ASIA-PACIFIC
  • 8.4. REST OF THE WORLD
    • 8.4.1. LATIN AMERICA
      • 8.4.1.1. BRAZIL
      • 8.4.1.2. MEXICO
      • 8.4.1.3. REST OF LATIN AMERICA
    • 8.4.2. MIDDLE-EAST AND AFRICA

9. COMPANY PROFILES

  • 9.1. ELI LILLY AND COMPANY
    • 9.1.1. OVERVIEW
    • 9.1.2. PRODUCT PORTFOLIO
    • 9.1.3. SWOT ANALYSIS
    • 9.1.4. STRATEGIC INITIATIVES
  • 9.2. ASTRAZENECA PLC.
    • 9.2.1. OVERVIEW
    • 9.2.2. PRODUCT PORTFOLIO
    • 9.2.3. SWOT ANALYSIS
    • 9.2.4. STRATEGIC INITIATIVES
  • 9.3. B.BRAUN MELSUNGEN AG
    • 9.3.1. OVERVIEW
    • 9.3.2. PRODUCT PORTFOLIO
    • 9.3.3. SWOT ANALYSIS
    • 9.3.4. STRATEGIC INITIATIVES
  • 9.4. NOVO NORDISK A/S
    • 9.4.1. OVERVIEW
    • 9.4.2. PRODUCT PORTFOLIO
    • 9.4.3. SWOT ANALYSIS
    • 9.4.4. STRATEGIC INITIATIVES
  • 9.5. SANOFI
    • 9.5.1. OVERVIEW
    • 9.5.2. PRODUCT PORTFOLIO
    • 9.5.3. SWOT ANALYSIS
    • 9.5.4. STRATEGIC INITIATIVES
  • 9.6. DIAVACS, INC.
    • 9.6.1. OVERVIEW
    • 9.6.2. PRODUCT PORTFOLIO
    • 9.6.3. SWOT ANALYSIS
  • 9.7. XOMA CORP.
    • 9.7.1. OVERVIEW
    • 9.7.2. PRODUCT PORTFOLIO
    • 9.7.3. SWOT ANALYSIS
    • 9.7.4. STRATEGIC INITIATIVES
  • 9.8. ALBIREO PHARMA INC.
    • 9.8.1. OVERVIEW
    • 9.8.2. PRODUCT PORTFOLIO
    • 9.8.3. SWOT ANALYSIS
  • 9.9. MACROGENICS, INC.
    • 9.9.1. OVERVIEW
    • 9.9.2. PRODUCT PORTFOLIO
    • 9.9.3. SWOT ANALYSIS
  • 9.10. ASTELLAS PHARMA
    • 9.10.1. OVERVIEW
    • 9.10.2. PRODUCT PORTFOLIO
    • 9.10.3. SWOT ANALYSIS
    • 9.10.4. STRATEGIC INITIATIVES
  • 9.11. GLAXOSMITHKLINE
    • 9.11.1. OVERVIEW
    • 9.11.2. PRODUCT PORTFOLIO
    • 9.11.3. SWOT ANALYSIS
  • 9.12. MERCK
    • 9.12.1. OVERVIEW
    • 9.12.2. PRODUCT PORTFOLIO
    • 9.12.3. SWOT ANALYSIS
    • 9.12.4. STRATEGIC INITIATIVES
  • 9.13. PFIZER
    • 9.13.1. OVERVIEW
    • 9.13.2. PRODUCT PORTFOLIO
    • 9.13.3. SWOT ANALYSIS
    • 9.13.4. STRATEGIC INITIATIVES
  • 9.14. XERIS PHARMACEUTICALS
    • 9.14.1. OVERVIEW
    • 9.14.2. PRODUCT PORTFOLIO
    • 9.14.3. SWOT ANALYSIS
    • 9.14.4. STRATEGIC INITIATIVES

LIST OF TABLES

  • TABLE 1: GLOBAL DIABETES DRUGS MARKET, BY GEOGRAPHY, 2018-2026 (IN $ BILLION)
  • TABLE 2: REGULATORY FRAMEWORK IN DIABETES DRUGS MARKET
  • TABLE 3: GLOBAL DIABETES DRUGS MARKET, BY DIABETES TYPES, 2018-2026, (IN $ BILLION)
  • TABLE 4: GLOBAL DIABETES DRUGS MARKET, BY TYPE 1 DIABETES, 2018-2026 (IN $ BILLIONS)
  • TABLE 5: GLOBAL DIABETES DRUGS MARKET, BY TYPE 2 DIABETES, 2018-2026 (IN $ BILLIONS)
  • TABLE 6: GLOBAL DIABETES DRUGS MARKET, BY PRODUCT CLASS, 2018-2026 (IN $ BILLIONS)
  • TABLE 7: GLOBAL DIABETES DRUGS MARKET, BY INSULIN TYPE, 2018-2026, (IN $ BILLION)
  • TABLE 8: GLOBAL DIABETES DRUGS MARKET, BY NON INSULIN DRUGS, 2018-2026 (IN $ BILLION)
  • TABLE 9: OPPORTUNITY MATRIX FOR DIABETES DRUGS MARKET
  • TABLE 10: VENDOR LANDSCAPE OF DIABETES DRUGS MARKET
  • TABLE 11: PIPELINE PORTFOLIO OF DIABETES DRUGS MARKET
  • TABLE 12: GLOBAL DIABETES DRUGS MARKET, BY GEOGRAPHY, 2018-2026, (IN $ BILLION)
  • TABLE 13: NORTH AMERICA DIABETES DRUGS MARKET, BY COUNTRY, 2018-2026 (IN $ BILLION)
  • TABLE 14: EUROPE DIABETES DRUGS MARKET, BY COUNTRY, 2018-2026 (IN $ BILLION)
  • TABLE 15: ASIA-PACIFIC DIABETES DRUGS MARKET, BY COUNTRY, 2018-2026 (IN $ BILLION)
  • TABLE 16: REST OF THE WORLD DIABETES DRUGS MARKET, BY REGION, 2018-2026 (IN $ BILLION)
  • TABLE 17: LATIN AMERICA DIABETES DRUGS MARKET, BY COUNTRY, 2018-2026 (IN $ BILLION)

LIST OF FIGURES

  • FIGURE 1: GLOBAL DIABETES DRUGS MARKET 2018-2026 (IN $ BILLION)
  • FIGURE 2: NORTH AMERICA DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 3: GLOBAL DIABETES DRUGS MARKET, BY TYPE 2 DIABETES, 2018-2026 (IN $ BILLION)
  • FIGURE 4: GLOBAL DIABETES DRUGS MARKET, BY INSULIN, 2018-2026 (IN $ BILLION)
  • FIGURE 5: AVERAGE LIFE EXPECTANCY AT BIRTH IN 2017, BY CONTINENT AND GENDER (IN YEARS)
  • FIGURE 6: GLOBAL DIABETES DRUGS MARKET, BY DIABETES TYPE, 2017 & 2026 (IN %)
  • FIGURE 7: GLOBAL DIABETES DRUGS MARKET, BY TYPE 1 DIABETES, 2018-2026 (IN $ BILLION)
  • FIGURE 8: GLOBAL DIABETES DRUGS MARKET, BY TYPE 2 DIABETES, 2018-2026 (IN $ BILLION)
  • FIGURE 9: GLOBAL DIABETES DRUGS MARKET, BY PRODUCT CLASS, 2018-2026 (IN $ BILLION)
  • FIGURE 10: GLOBAL DIABETES DRUGS MARKET, BY INSULIN, 2018-2026 (IN $ BILLION)
  • FIGURE 11: GLOBAL DIABETES DRUGS MARKET, BY FAST ACTING INSULIN, 2018-2026 (IN $ BILLION)
  • FIGURE 12: GLOBAL DIABETES DRUGS MARKET, BY INTERMEDIATE ACTING INSULIN, 2018-2026 (IN $ BILLION)
  • FIGURE 13: GLOBAL DIABETES DRUGS MARKET, BY LONG ACTING INSULIN, 2018-2026 (IN $ BILLION)
  • FIGURE 14: GLOBAL DIABETES DRUGS MARKET, BY NON-INSULIN, 2018-2026 (IN $ BILLION)
  • FIGURE 15: GLOBAL DIABETES DRUGS MARKET, BY DPP-4 INHIBITOR, 2018-2026 (IN $ BILLION)
  • FIGURE 16: GLOBAL DIABETES DRUGS MARKET, BY GLP-1 RECEPTORS AGONISTS, 2018-2026 (IN $ BILLION)
  • FIGURE 17: GLOBAL DIABETES DRUGS MARKET, BY SGLT-2 INHIBITORS, 2018-2026 (IN $ BILLION)
  • FIGURE 18: GLOBAL DIABETES DRUGS MARKET, BY OTHER NON INSULIN DRUGS, 2018-2026 (IN $ BILLION)
  • FIGURE 19: PORTER'S FIVE FORCE MODEL OF DIABETES DRUGS MARKET
  • FIGURE 20: KEY BUYING IMPACT ANALYSIS
  • FIGURE 21: GLOBAL DIABETES DRUGS MARKET, REGIONAL OUTLOOK, 2017 & 2026 (IN %)
  • FIGURE 22: NORTH AMERICA DIABETES DRUGS MARKET, 2017 & 2026 (IN %)
  • FIGURE 23: UNITED STATES DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 24: CANADA DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 25: EUROPE DIABETES DRUGS MARKET, 2017 & 2026 (IN %)
  • FIGURE 26: UNITED KINGDOM DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 27: FRANCE DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 28: GERMANY DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 29: RUSSIA DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 30: ITALY DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 31: DENMARK DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 32: NORWAY DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 33: AUSTRIA DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 34: SWITZERLAND DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 35: SWEDEN DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 36: NETHERLANDS DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 37: REST OF EUROPE DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 38: ASIA-PACIFIC DIABETES DRUGS MARKET, 2017 & 2026 (IN %)
  • FIGURE 39: CHINA DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 40: INDIA DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 41: AUSTRALIA DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 42: JAPAN DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 43: SOUTH KOREA DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 44: INDONESIA DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 45: MALAYSIA DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 46: PHILIPPINES DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 47: THAILAND DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 48: VIET NAM DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 49: REST OF ASIA-PACIFIC DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 50: LATIN AMERICA DIABETES DRUGS MARKET, 2017 & 2026 (IN %)
  • FIGURE 51: BRAZIL DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 52: MEXICO DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 53: REST OF LATIN AMERICA DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 54: MIDDLE-EAST AND AFRICA DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
Back to Top